feiwu.ran

Executive Director of Clinical Development; Medical oncologist, Beijing, China

[feiwu.ran @FeiwuRan]

I'll fly back to China after nearly 3 months' US visit!

[NuvationBio @nuvationbioinc]

#NuvationBio announces FDA approval of our new treatment for advanced ROS1-positive non-small cell lung cancer (#NSCLC) following priority review. Learn more: https://t.co/Dopi3hUU7T

[feiwu.ran @FeiwuRan]

Great news!

[ClinicalOncologyNews @ClinOncNews]

The FDA approved taletrectinib (Ibtrozi, Nuvation Bio), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

https://t.co/xsAVUgTyRy

[Hidehito HORINOUCHI @HHorinouchi]

🔥 @JCO_ASCO @ASCO 🆙
✅TRUST: Taletrectinib in ROS1+ NSCLC
🎯TKI-naïve/pretreated: ORR 88.8/55.8%, Intracranial-ORR 76.5/65.6%, mPFS 45.6/9.7mo
👥 @MP_3855 @n8pennell @MNagasaka @EnriquetaFelip Dr. Caicun Zhou
#LCSM @OncoAlert @ros1cancer @ros1dersuk
https://t.co/ta14FkTtbe

[NatureRevClinOncol @NatRevClinOncol]

New online! Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions https://t.co/TZtkkTB4Lr

[Blood Cancer Journal @BloodCancerJnl]

Progression-free survival as a surrogate endpoint in myeloma clinical trials. ⁦@_DrCP⁩ #OpenAccess

https://t.co/WA6Q8EJy0E

[NatureRevClinOncol @NatRevClinOncol]

In this new Review, Jeesun Yoon & Do-Youn Oh provide an update on the current landscape of HER2-targeted therapies beyond breast cancer: https://t.co/XxG2yVnpM9

[Toni Choueiri, MD @DrChoueiri]

1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC.

https://t.co/8hGQjmqZr6

[Cancer Cell @Cancer_Cell]

Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade https://t.co/YnDcigFEd1

[Tom Powles @tompowles1]

Enfortumab + Pembro outperforms platinum chemotherapy in advanced UC with a doubling of PFS and a halving of the risk of death @nejm. G3/4 AEs of 56% for EVP vs 70% for chemo & CR=29%. Editorial by @gniegisch ‘EVP is the new standard against which future trials must be compared’

[Hidehito HORINOUCHI @HHorinouchi]

🔥Therapy for Stage IV NSCLC Without Driver Alterations: @ASCO Living Guideline
🎯A must-read guideline for oncologists
🎙️@jaiyesi1 Dr. Naoki Furuya🇯🇵 @JCO_ASCO
#LCSM @OncoAlert
https://t.co/Th45X9h26A

[Hidehito HORINOUCHI @HHorinouchi]

🔥Therapy for Stage IV NSCLC With Driver Alterations:
@ASCO Living Guideline
🎯A must-read guideline for oncologists
🎙️@jaiyesi1 Dr. Naoki Furuya🇯🇵 @JCO_ASCO
#LCSM @OncoAlert
https://t.co/jbDBNE8fPt

[The Lancet Oncology @TheLancetOncol]

NEW: RANO propose a set of criteria for response assessment based on amino acid PET imaging in clinical trials enrolling participants with diffuse gliomas.

https://t.co/z4AsCEuK8G

[Journal for ImmunoTherapy of Cancer @jitcancer]

Countdown to 2024: #JITCTop10 - Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs https://t.co/JjPEJyFaJZ @TiansterZhang @FordePatrick @EladSharonMD @RCCadvocate @DrMarc15 @md_stewart

[Erman Akkus @Erman_Akkus]

📣Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)
@Annals_Oncology @myESMO

➡️ctDNA
➡️For now, plasma should be used. But in future, disease-specific sample may be used (urine, bile)
➡️In metastatic setting, used to evaluate the response. In earlier disease settings, it may be game changer to follow MRD and may lead treatment choice/intensity.
➡️Should be measured at multiple time points at regular intervals, incorporating with imaging
➡️Should be measured 4 weeks after surgery
➡️Solely or with imaging? Or when imaging fails to give definitive result? Head to head comparison between imaging and ctDNA would be ideal
➡️Technology: Detection of ctDNA mutations, methylation, tumor tissue-informed approach: standardizing is challenging
➡️Negative in baseline? Brain-only disease? Changes according to the type of therapy?
➡️In fact, clinical trials have started to incorporate ctDNA
➡️Regulatory issues

✅Authors suggested a useful trial design👇

👉https://t.co/zTXkS86kVE

@mgoudaMD @curijoey @VivekSubbiah @MDAndersonNews @ESMO_Open @EMA_News @FDAOncology @DenizCanGuven1 @DrHongchengZhu @pawel_sobczuk @ekocakavuk

#cancer #Oncology #treatment #MedX

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC position article and guidelines: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer https://t.co/sJKxuVlo6L @VanMorrisMD @mdmanishshah @DrRonanKelly

[Anirban Maitra @Aiims1742]

Huge #OpenAccess resource paper in @CD_AACR from @GustaveRoussy:
Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer 👉🏽
META-PRISM cohort of 1,031 refractory metastatic tumors with comprehensive molecular profiling.
https://t.co/mEhpS96GcH

[feiwu.ran @FeiwuRan]

Excellent review!

[Zihai Li, MD, PhD @Zihai]

https://t.co/b9LWO7iwcQ https://t.co/zmwTKt1XeA

[NatureRevClinOncol @NatRevClinOncol]

In a new Review, Itziar Otano, @AcUcero, @jon_zuga & @LuisPaz_Ares critically appraise the potential of immunotherapy for oncogene-addicted subsets of NSCLC: https://t.co/sXhhJUICs9
@CNIOStopCancer @unicomplutense @CIBERONC
@UAI_imas12 #imas12 #medonc #ImmunoOnc #LCSM